Anti-Coagulants - Belgium

Belgium

In Belgium, the Anti-Coagulants market is forecasted to attain a revenue of US$172.60m by the year 2024.
Looking ahead, it is anticipated that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of 6.95%, resulting in a market volume of US$241.50m by 2029.
When comparing globally, United States is expected to generate the highest revenue, amounting to US$16,740.00m in 2024.
Belgium has seen a surge in the use of direct oral anticoagulants as a preferred choice for patients with atrial fibrillation.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Belgium has been experiencing significant growth in recent years.

Customer preferences: Belgian customers have been increasingly turning to Anti-Coagulants as a preventative measure against blood clots, strokes, and other cardiovascular diseases. The aging population and the rising prevalence of obesity and diabetes have also contributed to the growing demand for these drugs.

Trends in the market: The Anti-Coagulants market in Belgium has been witnessing a shift towards newer oral anticoagulants (NOACs) over traditional anticoagulants such as warfarin. This trend is driven by the convenience and efficacy of NOACs, which require less monitoring and have fewer interactions with other drugs and food compared to warfarin. The market is also seeing an increase in the use of combination therapies, where NOACs are used in combination with antiplatelet drugs to prevent further cardiovascular events.

Local special circumstances: Belgium has a highly developed healthcare system, with universal health coverage and a strong emphasis on preventive care. The government has been actively promoting the use of NOACs over warfarin and has implemented policies to encourage the uptake of these drugs. This has led to a significant increase in the use of NOACs in the country.

Underlying macroeconomic factors: The Anti-Coagulants market in Belgium is also influenced by broader macroeconomic factors such as the country's GDP growth, healthcare spending, and regulatory environment. Belgium has a stable economy and a high level of healthcare spending, which supports the growth of the Anti-Coagulants market. The country's regulatory environment is also favorable towards the development and approval of new drugs, which has led to a diverse range of products being available in the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.